Ohr Pharmaceutical to Present at Upcoming Investment Conferences
NEW YORK, March 02, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive Officer, will present a corporate overview and business update at the upcoming 36th Annual Cowen & Company Global Healthcare Conference, and the 28th Annual ROTH Conference.
| 36th Annual Cowen & Company Global Healthcare Conference | |||||
| Date: | Monday, March 7 | ||||
| Time: | 3:20pm Eastern Time | ||||
| Location: | Salon C, Boston Marriott Copley Place, Boston, MA | ||||
| Webcast: | http://wsw.com/webcast/cowen30/ohrp | ||||
| 28th Annual ROTH Conference | |||||
| Date: | Tuesday, March 15 | ||||
| Time: | 3:00pm Pacific Time | ||||
| Location: | Salon 2 Blue, The Ritz Carlton Hotel, Dana Point | ||||
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead product, OHR-102 (Squalamine Lactate Ophthalmic Solution, 0.2%), is currently being studied as an eye drop formulation in clinical trials for back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. LifeSci Advisors, LLC Investor Relations Michael Wood 888-388-2327 646-597-6983 ir@ohrpharmaceutical.com mwood@lifesciadvisors.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
